Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
Regeneron stock rises, as profit, revenue and sales of SARS-CoV-2 antibody cocktail beat expectationsMarket Watch • 05/06/21
ATS 2021 Breaking News Session to Feature Pivotal Data on REGEN-COV™ (casirivimab with imdevimab) and Dupixent® (dupilumab)PRNewsWire • 05/03/21
New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 YearsPRNewsWire • 04/23/21